Our Programs
Related Links

  • For additional information on Attention Deficit/Hyperactivity Disorder, please visit the National Institute of Mental Health website.

    Click here
Home    >    Our Programs    >    ADHD and EB-1020

Our Programs : ADHD and EB-1020

EB-1020, A Norepinephrine and Dopamine-Preferring Triple for ADHD

EB-1020 is a triple reuptake inhibitor that modulates NE, DA and 5-HT in a ratio of 1 to 6 to 14, respectively. This preferential NE and DA reuptake inhibition profile with a small amount of 5-HT has the potential to be an effective treatment of ADHD while avoiding drug abuse liability.

 

The pharmacology of EB-1020 suggests a profile similar to atomoxetine (the first non-stimulant approved for ADHD), but with the additional effect on DA, which could improve attention and problem solving activity, as well as lead to a faster speed of onset and an improved cognitive profile. A recent study at Harvard conducted by Frank Tarazi, Ph.D. has been completed in which EB-1020 showed positive results in his animal model for ADHD. EB-1020 is now in a phase1 clinical trial for adult ADHD.

 

Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD is one of the most common childhood disorders and can continue through adolescence and into adulthood. Symptoms include difficulty staying focused and paying attention, difficulty controlling behavior, and hyperactivity (over-activity). ADHD causes significant impairment in adults resulting in difficulty functioning, low educational attainment, under achievement in vocational and educational pursuits, and poor social and family relations.

  • ADHD, one of the most common mental disorders in children and adolescents, also affects an estimated 4.1 percent of adults, ages 18-44, in a given year (Kessler 2005). Using the current 310 million population (US Census  2011) this represents approximately 10 million Americans
  • 41.3% of these people are classified as Severe. This represents approximately 1.7% of the adult population in the US or 4 million adults that are severely affected by ADHD.

Current pharmacotherapy of ADHD is not comprehensive for treating all symptoms and several of the standard treatments are associated with drug abuse liability and other side effects. Historically, patients suffering from ADHD have been treated with psychostimulants (e.g. amphetamines and its derivatives), although such medicines carry the risk of abuse. Only two non-stimulants have been approved for ADHD, atomoxetine, a norepinephrine reuptake inhibitor and guanfacine, an agonist of the α2A subtype of the NE receptor.

 

For additional information, please visit the National Institute of Mental Health website: http://www.nimh.nih.gov/statistics//1ADHD_ADULT.shtml

Source: National Institute of Mental Health; Euthymics Bioscience